Latest News and Press Releases

WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...

-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth...

WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord...

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include...

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include...

-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early...

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022,...

WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter...

WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company will host an Investor Day on Tuesday,...

-- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as...